DR ANTHONY WORLD BEST FOR MED CHEM BLOGS

Advertisements

PHASE 1-BMS-906024 by Bristol-Myers Squibb to treat breast, lung, and colon cancers and leukemia

New Drug Approvals

BMS-906024 is in Phase I clinical trials, both alone and in combination with other agents. Patients with colon, lung, breast, and other cancers are receiving intravenous doses of the compound to determine its safety and optimum dose ranges

New Phase I drug structure by Bristol-Myers Squibb disclosed at the spring 2013American Chemical Society meeting in New Orleans to treat breast, lung, and colon cancers and leukemia.[1] The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012,[2] and it currently being studied in clinical trials.[3][4]

 

View original post

phase 2-LGX818, Novartis Research Foundation to treat melanoma with a specific mutation in B-RAF kinase V600E

New Drug Approvals

LGX818

Methyl [(2S)-1-{[4-(3-{5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl}-1-isopropyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino}-2-propanyl]carbamate

Novartis Institutes for Biomedical Research and Genomics Institute of the Novartis Research Foundation to treat melanoma with a specific mutation in B-RAF kinase  V600E,  selective mutant B-RAF kinase inhibitor

LGX818 is currently in Phase Ib/II clinical trials. Patients with colon cancer or melanoma with the BRAF mutation, including patients resistant to other BRAF-targeted drugs, are receiving LGX818 pills alone or as part of drug cocktails to determine whether the drug is safe and efficacious

A phase Ib/II drug structure by Novartis disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat melanoma with a V600E mutation in the B-RAF kinase which it inhibits.[1][2][3]

Several clinical trials of LGX818 , either alone or in combinations with the MEK inhibitorMEK162[4], CDK4 inhibitor LEE011[5] are being run. The initial results are encouraging [6].

View original post 5 more words

PHASE 1- MGL-3196 (VIA-3196)Madrigal Pharmaceuticals, to treat high cholesterol/high triglycerides

New Drug Approvals

IMG_3814

MGL-3196 (VIA-3196)   photo credit The haystack  http://cenblog.org/the-haystack/tag/mgl-3196/
Madrigal Pharmaceuticals, acquired from VIA Pharmaceuticals, licensed from Roche to treat high cholesterol/high triglycerides , it mimics thyroid hormone, targeted to thyroid hormone receptor beta in the liver

Specifically, MGL-3196 is a thyroid hormone analog, designed to target a thyroid hormone receptor in the liver. These receptors regulate genes involved in cholesterol regulation and metabolism.

MGL-3196 is an orally administered, small-molecule liver-directed ß-selective THR agonist designed to specifically target receptors in the liver involved in metabolism and cholesterol regulation, and avoid side effects associated with thyroid hormone receptor activation outside the liver, including those mediated by THR-α receptors. MGL-3196 has currently completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower LDL cholesterol, triglyceride levels and Lp(a), and was inlicensed from Roche Pharmaceuticals. MGL-3196 has excellent safety in comparative studies with other THR agonists…

View original post 154 more words

PHASE 2 -TetraLogic’s BIRINAPANT for treatment of acute myeloid leukemia, pancreatic cancer, or ovarian cancer

New Drug Approvals

ChemSpider 2D Image | Birinapant | C42H56F2N8O6

BIRINAPANT, Apoptosis inhibitor

(2S,2’S)-N,N’-((2S,2’S)-((3S,3’S,5R,5’R)-5,5′-((6,6′-difluoro-1H,1’H-[2,2′-biindole]-3,3′-diyl)bis(methylene))bis(3-hydroxypyrrolidine-5,1-diyl))bis(1-oxobutane-2,1-diyl))bis(2-(methylamino)propanamide)

1260251-31-7 cas no

Birinapant is an antagonist of XIAP and cIAP1 with Kd value of 45 nM and <1 nM, respectively.

US20110003877,WO 2013049350 A1

Molecular Weight: 806.94
Birinapant Formula: C42H56F2N8O6

Birinapant, also known as TL32711,  is a synthetic small molecule and peptido mimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity. As a SMAC mimetic and IAP antagonist, TL32711 binds to and inhibits the activity of IAPs, such as X chromosome-linked IAP (XIAP) and cellular IAPs 1 and 2. Since IAPs shield cancer cells from the apoptosis process, this agent may restore and promote the induction of apoptosis through apoptotic signaling pathways in cancer cells. IAPs are overexpressed by many cancer cell types and suppress apoptosis by binding and inhibiting active caspases-3, -7 and -9…

View original post 1,661 more words

DR ANTHONY WORLD BEST FOR MED CHEM BLOGS

Srilanka-Chem

It is amazing that one person can inspire many

http://newdrugapprovals.wordpress.com/

see his websites

ANTHONY MELVIN CRASTO

DR ANTHONY MELVIN CRASTO Ph.D

GLENMARK SCIENTIST , NAVIMUMBAI, INDIA
web link picked up from mail signature of DR ANTHONY

http://anthonycrasto.jimdo.com/
http://www.anthonymelvincrasto.yolasite.com/ 
http://www.slidestaxx.com/anthony-melvin-crasto-phd 

http://amcrasto.wix.com/anthony-melvin-crasto/apps/blog
Congratulations! Your presentation titled “Anthony Crasto Glenmark scientist, helping millions with websites” has just crossed MILLION views.
アンソニー     安东尼   Энтони    안토니     أنتوني
join  process development group on google 

 

which is very popular across the world

ORGANIC CHEMISTRY SITE
JOIN COMMUNITY ON GOOGLE PLUS
http://amcrasto.webs.com/
http://newdrugapprovals.wordpress.com/

View original post

DR ANTHONY WORLD BEST FOR MED CHEM BLOGS

Srilanka-Chem

It is amazing that one person can inspire many

http://newdrugapprovals.wordpress.com/

see his websites

ANTHONY MELVIN CRASTO

DR ANTHONY MELVIN CRASTO Ph.D

GLENMARK SCIENTIST , NAVIMUMBAI, INDIA
web link picked up from mail signature of DR ANTHONY

http://anthonycrasto.jimdo.com/
http://www.anthonymelvincrasto.yolasite.com/ 
http://www.slidestaxx.com/anthony-melvin-crasto-phd 

http://amcrasto.wix.com/anthony-melvin-crasto/apps/blog
Congratulations! Your presentation titled “Anthony Crasto Glenmark scientist, helping millions with websites” has just crossed MILLION views.
アンソニー     安东尼   Энтони    안토니     أنتوني
join  process development group on google 

 

which is very popular across the world

ORGANIC CHEMISTRY SITE
JOIN COMMUNITY ON GOOGLE PLUS
http://amcrasto.webs.com/
http://newdrugapprovals.wordpress.com/

View original post